NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Provided By GlobeNewswire
Last update: Nov 18, 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –
– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –
Read more at globenewswire.com20.03
+0.9 (+4.7%)
NASDAQ:NAMSW (5/1/2025, 9:19:32 PM)
9.23
-0.19 (-2.02%)
Find more stocks in the Stock Screener
